# ELTX catalysts: Elicio Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/eltx/catalysts

> Elicio Therapeutics, Inc. (ELTX) has no upcoming catalysts in this calendar. The latest recorded is the Elicio Therapeutics, Inc. earnings report, November 5, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Elicio Therapeutics, Inc. |
| Ticker | ELTX (Nasdaq) |
| SEC CIK | 1601485 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/eltx |

## Cash runway

Cash $30.9M as of 2026-09-30; quarterly burn $10.4M; about 8.9 months of runway at that rate (XBRL company facts, accession 0001601485-26-000066).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2023 | [ELI-002 trial start](https://sec-api.dev/pdufa/eli-002) | ELTX |  | completed | "In October 2023, we completed enrollment of the AMPLIFY-7P Phase 1 portion of the trial for ELI-002 7P and initiated enrollment of the AMPLIFY-7P Phase 2 portion of the trial in January 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1601485/000160148526000056/eltx-20260630.htm)) |
| Jan 2024 | [ELI-002 trial start](https://sec-api.dev/pdufa/eli-002) | ELTX |  | completed | "We initiated enrollment of the Phase 2 of the AMPLIFY-7P trial in January 2024 and we have not yet initiated clinical trials for any other product candidates." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1601485/000160148525000049/angn-20241231.htm)) |
| November 13, 2024 | [Elicio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/eltx/catalysts) | ELTX |  | completed | "Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates AMPLIFY-7P Phase 2 randomized study anticipated to complete enrollment in Q4 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148524000074/q3earnings_prx11-12x24xf.htm)) |
| Q2 2025 | [ELI-002 interim data readout](https://sec-api.dev/pdufa/eli-002) | ELTX |  | scheduled | "We are pleased to have strengthened our balance sheet, and such funding is expected to support operations into Q2 2025, beyond the anticipated AMPLIFY-7P interim analysis."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148524000074/q3earnings_prx11-12x24xf.htm)) |
| May 13, 2025 | [ELI-002 earnings report](https://sec-api.dev/pdufa/eli-002) | ELTX |  | completed | "Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates Interim analysis focused on disease-free survival ("DFS") in randomized Phase 2 AMPLIFY- 7P clinical trial expected in Q3 2025 Company has alignment with U.S. Food and Drug Administration ("FDA") on key design elements of planned Phase 3 study of ELI-002 Current cash position expected to support operations beyond anticipated AMPLIFY-7P Phase 2 interim analysis BOSTON, May 13, 2025 — Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate and clinical updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148525000072/a2025-05x13xxeltxxx1q25f.htm)) |
| Q3 2025 | [ELI-002 interim data readout](https://sec-api.dev/pdufa/eli-002) | ELTX |  | scheduled | "This study is progressing toward a disease-free survival event-driven interim analysis expected in the third quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1601485/000160148525000074/angn-20250331.htm)) |
| August 7, 2025 | [ELI-002 earnings report](https://sec-api.dev/pdufa/eli-002) | ELTX |  | completed | "Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates Recent positive recommendation by the Independent Data Monitoring Committee ("IDMC") to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event-driven final analysis focused on disease-free survival ("DFS") expected in Q4 2025 Secured $10 million financing in Q2 2025; Current cash position expected to support operations beyond anticipated AMPLIFY-7P Phase 2 final analysis BOSTON, August 7, 2025 — Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio" or the "Company"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate and clinical updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148525000108/a2025-08x07xxeltxxx2q25f.htm)) |
| Q4 2025 | [ELI-002 interim data readout](https://sec-api.dev/pdufa/eli-002) | ELTX |  | scheduled | "The Company expects that its current cash and cash equivalents will support operations into Q4 2025, beyond the anticipated AMPLIFY-7P Phase 2 interim analysis." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148525000072/a2025-05x13xxeltxxx1q25f.htm)) |
| Oct 2025 | [ELI-002 trial start](https://sec-api.dev/pdufa/eli-002) | ELTX |  | completed | "Responses were observed across all seven mKRAS epitopes and occurred across a diverse HLA background, highlighting ELI-002 7P's potential to benefit a broad and genetically diverse patient population.  In October 2025, Elicio announced robust T cell responses across diverse HLA backgrounds in the ongoing Phase 2 AMPLIFY-7P trial.  In September 2025, Elicio announced the planned investigator-initiated Phase 1 neoadjuvant trial of ELI-002 7P in resectable and borderline resectable PDAC led by Memorial Sloan Kettering Cancer Center and funded by the Lustgarten Foundation, assessing ELI-002 7P combined with mFOLFIRINOX with or without the anti-PD-1 antibody." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148525000123/elicioq325prdraft_111320.htm)) |
| November 13, 2025 | [Elicio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/eltx/catalysts) | ELTX |  | completed | "Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates  In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ("PDAC"), fewer disease progressions and deaths than projected have been observed as of November 6, 2025.  Based on 2:1 randomization with twice as many patients in the ELI-002 7P treatment arm compared to the observation arm, Elicio believes the lower-than-projected number of disease progressions and deaths may reflect a favorable impact on disease-free survival ("DFS")" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148525000123/elicioq325prdraft_111320.htm)) |
| Q1 2026 | [ELI-002 trial start](https://sec-api.dev/pdufa/eli-002) | ELTX |  | scheduled | "the timing of initiation of our planned clinical trials, including the initiation of an ELI-002 Phase 1B in colorectal cancer, the initiation of ELI-002 combination studies, and our anticipated Phase 3 readiness in the first quarter of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148524000107/eliciocorporatedeck_dece.htm)) |
| 1H 2026 | [ELI-002 topline data readout](https://sec-api.dev/pdufa/eli-002) | ELTX |  | scheduled | "In 2025, Elicio continued advancement of the randomized Phase 2 AMPLIFY-7P trial in post-resection mKRAS PDAC, with the event-driven primary DFS analysis remaining on track for an anticipated 1H 2026 readout" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148526000026/elicioq425prdraft_31226.htm)) |
| March 12, 2026 | [Elicio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/eltx/catalysts) | ELTX |  | completed | "Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148526000026/elicioq425prdraft_31226.htm)) |
| May 11, 2026 | [Elicio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/eltx/catalysts) | ELTX |  | completed | "Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148526000041/eltx1q26pr.htm)) |
| August 13, 2026 | [ELI-002 trial start](https://sec-api.dev/pdufa/eli-002) | ELTX |  | completed | "Announced the activation of an investigator-initiated Phase 1 neoadjuvant trial evaluating ELI-002 7P plus chemotherapy and an anti-PD-1 checkpoint inhibitor in borderline resectable and resectable pancreatic ductal adenocarcinoma ("PDAC")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148526000055/eltx2q26pr.htm)) |
| August 13, 2026 | [Elicio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/eltx/catalysts) | ELTX |  | completed | "Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148526000055/eltx2q26pr.htm)) |
| Q4 2026 | [ELI-002 interim data readout](https://sec-api.dev/pdufa/eli-002) | ELTX |  | scheduled | ""Our recent financing provided us with the capital needed to evaluate initial data from our planned Phase 1 combination study of ELI-002 7P with a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor, which is anticipated to begin in the fourth quarter of this year." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148526000055/eltx2q26pr.htm)) |
| Q4 2026 | [Camupepimut trial start](https://sec-api.dev/pdufa/camupepimut) | ELTX |  | scheduled | "Elicio is targeting a Q4 2026 initiation of a Phase 1 study evaluating camupepimut with daraxonrasib, with or without nivolumab, in metastatic KRAS-mutated PDAC." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148526000065/q3earningspr11-5x26final.htm)) |
| Q4 2026 | [ELI-002 trial start](https://sec-api.dev/pdufa/eli-002) | ELTX |  | scheduled | "Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor in metastatic pancreatic cancer; Phase 1 study anticipated to initiate Q4 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148526000055/eltx2q26pr.htm)) |
| November 5, 2026 | [Elicio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/eltx/catalysts) | ELTX |  | completed | "Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148526000065/q3earningspr11-5x26final.htm)) |

## Drugs

- [Camupepimut](https://sec-api.dev/pdufa/camupepimut): 
- [ELI-002](https://sec-api.dev/pdufa/eli-002): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/eltx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ELTX catalysts: Elicio Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/eltx/catalysts

```bibtex
@misc{secapidev_companies_eltx_catalysts_20261116,
  title        = {ELTX catalysts: Elicio Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/eltx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_eltx_catalysts_20261116","title":"ELTX catalysts: Elicio Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/eltx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
